文献速递中枢神经肿瘤放疗姑息放疗与转移瘤

分次立体定向放疗对进展性/复发性胶质母细胞瘤患者日常生活活动能力和体能状态的影响:一项回顾性研究

Impact of fractionated stereotactic radiotherapy on activity of daily living and performance status in progressive/recurrent glioblastoma: a retrospective study.
PubMed 文献 · Radiat Oncol · 2022-12-06

该回顾性研究纳入2010年10月至2017年11月在洛林癌症研究所接受分次立体定向放疗的59例复发性胶质母细胞瘤患者,处方剂量为25 Gy分5次、5-7天完成(80%等剂量线)。全组KPS和ADL受损发生率分别为51.9%和37.8%,PTV大小对KPS有不利影响(HR=1.57,95%CI 1.19-2.08,p=0.028);仅2例出现早期3级毒性,无4级或晚期毒性。

要点

  • 59例复发性GBM接受25 Gy/5次fSRT(80%等剂量线),KPS和ADL受损发生率分别为51.9%和37.8%。
  • PTV大小对KPS有不利影响(HR=1.57,95%CI 1.19-2.08,p=0.028)。
  • 仅2例出现早期3级毒性,无4级或晚期毒性;初次手术与更好的PFS相关(HR=0.48,95%CI 0.27-0.86,p=0.013)。

核心结论

  • 作者认为,在使用fSRT治疗复发性GBM时,较大的PTV预测较低的KPS。

研究设计与样本

  • 回顾性收集2010年10月至2017年11月在洛林癌症研究所接受fSRT的复发性GBM患者数据,分析哪些因素与较低的KPS评分相关。

主要发现

  • 59例患者接受25 Gy分5次、5-7天完成(80%等剂量线)的fSRT,从初次放疗结束到fSRT开始的中位时间为10.7个月,fSRT开始后的中位随访时间为8.8个月。
  • 全组KPS和ADL受损发生率分别为51.9%和37.8%,PTV大小对KPS有不利影响(HR=1.57,95%CI 1.19-2.08,p=0.028)。
  • 仅2例出现早期3级毒性,无4级或晚期毒性。
  • 中位总生存时间、fSRT后中位总生存时间、中位无进展生存时间和无机构化生存时间分别为25.8、8.8、3.9和7.7个月。
  • 初次手术与更好的无进展生存相关(HR=0.48,95%CI 0.27-0.86,p=0.013)。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: The prognosis of recurrent glioblastoma (GBM) is poor, with limited options of palliative localized or systemic treatments. Survival can be improved by a second localized treatment; however, it is not currently possible to identify which patients would benefit from this approach. This study aims to evaluate which factors lead to a lower Karnofsky performance status (KPS) score after fractionated stereotactic RT (fSRT). METHODS: We retrospectively collected data from patients treated with fSRT for recurrent GBM at the Institut de Cancérologie de Lorraine between October 2010 and November 2017 and analyzed which factors were associated with a lower KPS score. RESULTS: 59 patients received a dose of 25 Gy in 5 sessions spread over 5-7 days (80% isodose). The median time from the end of primary radiotherapy to the initiation of fSRT was 10.7 months. The median follow-up after fSRT initiation was 8.8 months. The incidence of KPS and ADL impairment in all patients were 51.9% and 37.8% respectively with an adverse impact of PTV size on KPS (HR = 1.57 [95% CI 1.19-2.08], p = 0.028). Only two patients showed early grade 3 toxicity and none showed grade 4 or late toxicity. The median overall survival time, median overall survival time after fSRT, median progression-free survival and institutionalization-free survival times were 25.8, 8.8, 3.9 and 7.7 months, respectively. Initial surgery was associated with better progression-free survival (Hazard ratio (HR) = 0.48 [95% CI 0.27-0.86], p = 0.013). CONCLUSIONS: A larger PTV should predicts lower KPS in the treatment of recurrent GBM using fSRT.

来源:Radiat Oncol,查看原文。版权归原作者所有。

引用

  1. Demogeot N, Salleron J, Rech F, et al. Impact of fractionated stereotactic radiotherapy on activity of daily living and performance status in progressive/recurrent glioblastoma: a retrospective study. Radiat Oncol. 2022. PMID: 36474245. doi:10.1186/s13014-022-02169-1

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。